Payment overview · 2025
General Payments
$716.81
22 reported records · 10 companies
Healthcare provider profile · identity verified
Charles Marler, M.D.
Allopathic & Osteopathic Physicians|Family Medicine · GREAT FALLS, MT · NPI 1407847155
Verified facts
What the public records show
CMS Open Payments records show Charles Marler, M.D. received $716.81 in general payments during 2025 across 22 reported records.
AstraZeneca Pharmaceuticals LP accounted for 43.7% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 17 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Farxiga, Mounjaro, Trelegy Ellipta.
Astellas Pharma US Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Myrbetriq as an associated drug or biological on 16 records involving 16 distinct recipient NPIs. Public Medicare Part D data also shows 62 claims for Myrbetriq by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported BRILINTA as an associated drug or biological on 993 records involving 512 distinct recipient NPIs. Public Medicare Part D data also shows 21 claims for Brilinta by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported FARXIGA as an associated drug or biological on 106133 records involving 42906 distinct recipient NPIs. Public Medicare Part D data also shows 46 claims for Farxiga by this doctor in 2024.
GlaxoSmithKline, LLC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRELEGY ELLIPTA as an associated drug or biological on 131532 records involving 37148 distinct recipient NPIs. Public Medicare Part D data also shows 38 claims for Trelegy Ellipta by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported MOUNJARO as an associated drug or biological on 186719 records involving 66436 distinct recipient NPIs. Public Medicare Part D data also shows 19 claims for Mounjaro by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRULICITY as an associated drug or biological on 71 records involving 57 distinct recipient NPIs. Public Medicare Part D data also shows 13 claims for Trulicity by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Ozempic as an associated drug or biological on 261625 records involving 77793 distinct recipient NPIs. Public Medicare Part D data also shows 51 claims for Ozempic by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ELIQUIS as an associated drug or biological on 87112 records involving 36032 distinct recipient NPIs. Public Medicare Part D data also shows 73 claims for Eliquis by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| AstraZeneca Pharmaceuticals LP | Unresolved — no canonical attribution shown | $313.02 | 43.7% | 5 | 2025 |
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | Unresolved — no canonical attribution shown | $98.69 | 13.8% | 3 | 2025 |
| ABBVIE INC. | Unresolved — no canonical attribution shown | $77.01 | 10.7% | 3 | 2025 |
| Astellas Pharma US Inc | Unresolved — no canonical attribution shown | $67.26 | 9.4% | 2 | 2025 |
| Amgen Inc. | Unresolved — no canonical attribution shown | $62.23 | 8.7% | 3 | 2025 |
| PFIZER INC. | Unresolved — no canonical attribution shown | $37.71 | 5.3% | 2 | 2025 |
| GlaxoSmithKline, LLC. | Unresolved — no canonical attribution shown | $16.25 | 2.3% | 1 | 2025 |
| Novo Nordisk Inc | Unresolved — no canonical attribution shown | $16.09 | 2.2% | 1 | 2025 |
| Otsuka America Pharmaceutical, Inc. | Unresolved — no canonical attribution shown | $15.09 | 2.1% | 1 | 2025 |
| Lilly USA, LLC | Unresolved — no canonical attribution shown | $13.46 | 1.9% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $716.81 | 22 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| AIRSUPRA Normalized: airsupra |
Drug | AstraZeneca Pharmaceuticals LP | $313.02 | 5 | 2025 |
Source payment records
|
|||||
| BREZTRI Normalized: breztri |
Drug | AstraZeneca Pharmaceuticals LP | $125.85 | 1 | 2025 |
Source payment records
|
|||||
| FARXIGA Normalized: farxiga |
Drug | AstraZeneca Pharmaceuticals LP | $125.85 | 1 | 2025 |
Source payment records
|
|||||
| CAPLYTA Normalized: caplyta |
Drug | ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | $98.69 | 3 | 2025 |
Source payment records
|
|||||
| Veozah Normalized: veozah |
Drug | Astellas Pharma US Inc | $67.26 | 2 | 2025 |
Source payment records
|
|||||
| QULIPTA Normalized: qulipta |
Drug | ABBVIE INC. | $62.36 | 2 | 2025 |
Source payment records
|
|||||
| UBRELVY Normalized: ubrelvy |
Drug | ABBVIE INC. | $62.36 | 2 | 2025 |
Source payment records
|
|||||
| OTEZLA Normalized: otezla |
Drug | Amgen Inc. | $62.23 | 3 | 2025 |
Source payment records
|
|||||
| REPATHA Normalized: repatha |
Biological | Amgen Inc. | $62.23 | 3 | 2025 |
Source payment records
|
|||||
| NURTEC ODT Normalized: nurtec odt |
Drug | PFIZER INC. | $37.71 | 2 | 2025 |
Source payment records
|
|||||
| ZAVZPRET Normalized: zavzpret |
Drug | PFIZER INC. | $37.71 | 2 | 2025 |
Source payment records
|
|||||
| TRELEGY ELLIPTA Normalized: trelegy ellipta |
Drug | GlaxoSmithKline, LLC. | $16.25 | 1 | 2025 |
Source payment records
|
|||||
| Wegovy Normalized: wegovy |
Drug | Novo Nordisk Inc | $16.09 | 1 | 2025 |
Source payment records
|
|||||
| REXULTI Normalized: rexulti |
Drug | Otsuka America Pharmaceutical, Inc. | $15.09 | 1 | 2025 |
Source payment records
|
|||||
| VRAYLAR Normalized: vraylar |
Drug | ABBVIE INC. | $14.65 | 1 | 2025 |
Source payment records
|
|||||
| MOUNJARO Normalized: mounjaro |
Drug | Lilly USA, LLC | $13.46 | 1 | 2025 |
Source payment records
|
|||||
| ZEPBOUND Normalized: zepbound |
Drug | Lilly USA, LLC | $13.46 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| FARXIGA farxiga |
2025 | Farxiga | 2024 | 46 | exact normalized | Medicare Part D |
| MOUNJARO mounjaro |
2025 | Mounjaro | 2024 | 19 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| TRELEGY ELLIPTA trelegy ellipta |
2025 | Trelegy Ellipta | 2024 | 38 Beneficiary count suppressed |
exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| Astellas Pharma US Inc Exact reporting entity; no affiliate inference |
2025 | Myrbetriq open payments reported associated product |
CMS Open Payments — General Payments 16 supporting records · 16 recipient NPIs · example record 1238599014 |
Myrbetriq · 2024 Exact normalized brand match · 1 Part D row |
62 | 15 |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | BRILINTA open payments reported associated product |
CMS Open Payments — General Payments 993 supporting records · 512 recipient NPIs · example record 1206131430 |
Brilinta · 2024 Exact normalized brand match · 1 Part D row |
21 | suppressed by CMS |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | FARXIGA open payments reported associated product |
CMS Open Payments — General Payments 106133 supporting records · 42906 recipient NPIs · example record 1206131362 |
Farxiga · 2024 Exact normalized brand match · 1 Part D row |
46 | 12 |
| GlaxoSmithKline, LLC. Exact reporting entity; no affiliate inference |
2025 | TRELEGY ELLIPTA open payments reported associated product |
CMS Open Payments — General Payments 131532 supporting records · 37148 recipient NPIs · example record 1190332369 |
Trelegy Ellipta · 2024 Exact normalized brand match · 1 Part D row |
38 | suppressed by CMS |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | MOUNJARO open payments reported associated product |
CMS Open Payments — General Payments 186719 supporting records · 66436 recipient NPIs · example record 1186464455 |
Mounjaro · 2024 Exact normalized brand match · 1 Part D row |
19 | suppressed by CMS |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | TRULICITY open payments reported associated product |
CMS Open Payments — General Payments 71 supporting records · 57 recipient NPIs · example record 1186464601 |
Trulicity · 2024 Exact normalized brand match · 1 Part D row |
13 | suppressed by CMS |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Ozempic open payments reported associated product |
CMS Open Payments — General Payments 261625 supporting records · 77793 recipient NPIs · example record 1188130076 |
Ozempic · 2024 Exact normalized brand match · 1 Part D row |
51 | 12 |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | ELIQUIS open payments reported associated product |
CMS Open Payments — General Payments 87112 supporting records · 36032 recipient NPIs · example record 1228794063 |
Eliquis · 2024 Exact normalized brand match · 1 Part D row |
73 | 22 |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Pantoprazole Sodium | Pantoprazole Sodium | 320 | 89 |
| Atorvastatin Calcium | Atorvastatin Calcium | 315 | 59 |
| Gabapentin | Gabapentin | 275 | 54 |
| Levothyroxine Sodium | Levothyroxine Sodium | 272 | 77 |
| Potassium Chloride | Potassium Chloride | 269 | 66 |
| Amlodipine Besylate | Amlodipine Besylate | 262 | 54 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 248 | 60 |
| Losartan Potassium | Losartan Potassium | 235 | 58 |
| Tamsulosin Hcl | Tamsulosin Hcl | 227 | 41 |
| Lisinopril | Lisinopril | 214 | 44 |
| Metoprolol Succinate | Metoprolol Succinate | 205 | 45 |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 201 | 68 |
| Duloxetine Hcl | Duloxetine Hcl | 181 | 27 |
| Metformin Hcl Er | Metformin Hcl | 178 | 39 |
| Omeprazole | Omeprazole | 172 | 35 |
| Furosemide | Furosemide | 166 | 45 |
| Donepezil Hcl | Donepezil Hcl | 161 | 28 |
| Trazodone Hcl | Trazodone Hcl | 142 | 27 |
| Metformin Hcl | Metformin Hcl | 132 | 22 |
| Januvia | Sitagliptin Phosphate | 129 | 15 |
| Pregabalin | Pregabalin | 118 | 19 |
| Citalopram Hbr | Citalopram Hydrobromide | 113 | 21 |
| Finasteride | Finasteride | 107 | 18 |
| Buspirone Hcl | Buspirone Hcl | 97 | 22 |
| Ropinirole Hcl | Ropinirole Hcl | 97 | 16 |
| Carvedilol | Carvedilol | 94 | 22 |
| Carbidopa-Levodopa | Carbidopa/Levodopa | 84 | suppressed |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 83 | 31 |
| Montelukast Sodium | Montelukast Sodium | 83 | 19 |
| Oxycodone-Acetaminophen | Oxycodone Hcl/Acetaminophen | 81 | 18 |
| Mirtazapine | Mirtazapine | 79 | 14 |
| Clonazepam | Clonazepam | 77 | 13 |
| Doxepin Hcl | Doxepin Hcl | 77 | 14 |
| Meloxicam | Meloxicam | 77 | 18 |
| Pravastatin Sodium | Pravastatin Sodium | 76 | 17 |
| Sertraline Hcl | Sertraline Hcl | 74 | 15 |
| Eliquis | Apixaban | 73 | 22 |
| Aripiprazole | Aripiprazole | 72 | suppressed |
| Memantine Hcl | Memantine Hcl | 72 | 12 |
| Quetiapine Fumarate | Quetiapine Fumarate | 72 | 14 |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 72 | 13 |
| Oxycodone Hcl | Oxycodone Hcl | 70 | 25 |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 66 | suppressed |
| Spironolactone | Spironolactone | 66 | 22 |
| Celecoxib | Celecoxib | 65 | 15 |
| Hydrochlorothiazide | Hydrochlorothiazide | 65 | 16 |
| Myrbetriq | Mirabegron | 62 | 15 |
| Warfarin Sodium | Warfarin Sodium | 62 | 16 |
| Tramadol Hcl | Tramadol Hcl | 60 | 19 |
| Hydroxyzine Hcl | Hydroxyzine Hcl | 58 | 11 |
| Oxcarbazepine | Oxcarbazepine | 58 | suppressed |
| Simvastatin | Simvastatin | 58 | 17 |
| Baclofen | Baclofen | 57 | 12 |
| Prazosin Hcl | Prazosin Hcl | 57 | suppressed |
| Xarelto | Rivaroxaban | 54 | suppressed |
| Allopurinol | Allopurinol | 53 | 15 |
| Alendronate Sodium | Alendronate Sodium | 52 | suppressed |
| Metoprolol Tartrate | Metoprolol Tartrate | 52 | 17 |
| Ondansetron Odt | Ondansetron | 52 | 38 |
| Ozempic | Semaglutide | 51 | 12 |
| Topiramate | Topiramate | 50 | suppressed |
| Tizanidine Hcl | Tizanidine Hcl | 48 | 16 |
| Ezetimibe | Ezetimibe | 47 | 13 |
| Farxiga | Dapagliflozin Propanediol | 46 | 12 |
| Prednisone | Prednisone | 46 | 30 |
| Tramadol Hcl Er | Tramadol Hcl | 46 | suppressed |
| Paroxetine Hcl | Paroxetine Hcl | 45 | suppressed |
| Escitalopram Oxalate | Escitalopram Oxalate | 44 | 12 |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 44 | 16 |
| Ventolin Hfa | Albuterol Sulfate | 44 | suppressed |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 43 | 16 |
| Clopidogrel | Clopidogrel Bisulfate | 41 | 16 |
| Bupropion Hcl Sr | Bupropion Hcl | 40 | suppressed |
| Glimepiride | Glimepiride | 40 | suppressed |
| Lactulose | Lactulose | 39 | suppressed |
| Butalbital-Acetaminophen-Caffe | Butalb/Acetaminophen/Caffeine | 38 | suppressed |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 38 | suppressed |
| Famotidine | Famotidine | 36 | 11 |
| Clonidine Hcl | Clonidine Hcl | 34 | suppressed |
| Divalproex Sodium | Divalproex Sodium | 34 | suppressed |
| Bupropion Xl | Bupropion Hcl | 33 | suppressed |
| Ondansetron Hcl | Ondansetron Hcl | 33 | suppressed |
| Propranolol Hcl | Propranolol Hcl | 33 | suppressed |
| Diclofenac Sodium | Diclofenac Sodium | 31 | 17 |
| Fluticasone Propionate | Fluticasone Propionate | 31 | 15 |
| Fenofibrate | Fenofibrate Nanocrystallized | 30 | suppressed |
| Oxybutynin Chloride Er | Oxybutynin Chloride | 30 | suppressed |
| Sucralfate | Sucralfate | 30 | 13 |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 30 | 11 |
| Diltiazem 24hr Er (Cd) | Diltiazem Hcl | 29 | suppressed |
| Amitriptyline Hcl | Amitriptyline Hcl | 27 | suppressed |
| Azithromycin | Azithromycin | 26 | 20 |
| Metoclopramide Hcl | Metoclopramide Hcl | 25 | suppressed |
| Novolog Flexpen | Insulin Aspart | 25 | suppressed |
| Diltiazem Hcl | Diltiazem Hcl | 24 | suppressed |
| Fluoxetine Hcl | Fluoxetine Hcl | 24 | suppressed |
| Lorazepam | Lorazepam | 24 | suppressed |
| Morphine Sulfate | Morphine Sulfate | 24 | suppressed |
| Bumetanide | Bumetanide | 23 | suppressed |
| Fentanyl | Fentanyl | 23 | suppressed |
| Nifedipine Er | Nifedipine | 23 | suppressed |
| Valacyclovir | Valacyclovir Hcl | 23 | suppressed |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 22 | suppressed |
| Loperamide | Loperamide Hcl | 22 | suppressed |
| Methocarbamol | Methocarbamol | 22 | suppressed |
| Brilinta | Ticagrelor | 21 | suppressed |
| Olanzapine | Olanzapine | 21 | suppressed |
| Propranolol Hcl Er | Propranolol Hcl | 21 | suppressed |
| Sulfamethoxazole-Trimethoprim | Sulfamethoxazole/Trimethoprim | 21 | 12 |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 20 | 16 |
| Digoxin | Digoxin | 20 | suppressed |
| Fluconazole | Fluconazole | 20 | 12 |
| Levetiracetam | Levetiracetam | 20 | suppressed |
| Memantine Hcl Er | Memantine Hcl | 20 | suppressed |
| Alprazolam | Alprazolam | 19 | suppressed |
| Clonidine | Clonidine | 19 | suppressed |
| Fluticasone-Salmeterol | Fluticasone Propion/Salmeterol | 19 | suppressed |
| Mounjaro | Tirzepatide | 19 | suppressed |
| Irbesartan | Irbesartan | 17 | suppressed |
| Methadone Hcl | Methadone Hcl | 17 | suppressed |
| Nystatin | Nystatin | 17 | suppressed |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 16 | suppressed |
| Glipizide Er | Glipizide | 16 | suppressed |
| Hydralazine Hcl | Hydralazine Hcl | 16 | suppressed |
| Midodrine Hcl | Midodrine Hcl | 16 | suppressed |
| Nitrofurantoin Mono-Macro | Nitrofurantoin Monohyd/M-Cryst | 16 | suppressed |
| Pramipexole Dihydrochloride | Pramipexole Di-Hcl | 16 | suppressed |
| Risperidone | Risperidone | 16 | suppressed |
| Breztri Aerosphere | Budesonide/Glycopyr/Formoterol | 15 | suppressed |
| Chlorthalidone | Chlorthalidone | 15 | suppressed |
| Doxazosin Mesylate | Doxazosin Mesylate | 15 | suppressed |
| Fenofibrate | Fenofibrate | 15 | suppressed |
| Ibu | Ibuprofen | 15 | suppressed |
| Promethazine Hcl | Promethazine Hcl | 15 | suppressed |
| Tresiba Flextouch U-200 | Insulin Degludec | 15 | suppressed |
| Zolpidem Tartrate | Zolpidem Tartrate | 15 | suppressed |
| Amiodarone Hcl | Amiodarone Hcl | 14 | suppressed |
| Buprenorphine | Buprenorphine | 14 | suppressed |
| Fludrocortisone Acetate | Fludrocortisone Acetate | 14 | suppressed |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 14 | suppressed |
| Vilazodone Hcl | Vilazodone Hcl | 14 | suppressed |
| Atenolol | Atenolol | 13 | suppressed |
| Dicyclomine Hcl | Dicyclomine Hcl | 13 | suppressed |
| Divalproex Sodium Er | Divalproex Sodium | 13 | suppressed |
| Estradiol | Estradiol | 13 | suppressed |
| Hydromorphone Hcl | Hydromorphone Hcl | 13 | suppressed |
| Pioglitazone Hcl | Pioglitazone Hcl | 13 | suppressed |
| Trulicity | Dulaglutide | 13 | suppressed |
| Cephalexin | Cephalexin | 12 | suppressed |
| Indomethacin | Indomethacin | 12 | suppressed |
| Latanoprost | Latanoprost | 12 | suppressed |
| Meclizine Hcl | Meclizine Hcl | 12 | suppressed |
| Morphine Sulfate Er | Morphine Sulfate | 12 | suppressed |
| Oxybutynin Chloride | Oxybutynin Chloride | 12 | suppressed |
| Torsemide | Torsemide | 12 | suppressed |
| Alfuzosin Hcl Er | Alfuzosin Hcl | 11 | suppressed |
| Cholestyramine | Cholestyramine (With Sugar) | 11 | suppressed |
| Eszopiclone | Eszopiclone | 11 | suppressed |
| Hydrocortisone | Hydrocortisone | 11 | suppressed |
| Hydroxyzine Pamoate | Hydroxyzine Pamoate | 11 | suppressed |
| Phenytoin Sodium Extended | Phenytoin Sodium Extended | 11 | suppressed |
| Potassium Citrate Er | Potassium Citrate | 11 | suppressed |
| Sevelamer Carbonate | Sevelamer Carbonate | 11 | suppressed |
| Triamterene-Hydrochlorothiazid | Triamterene/Hydrochlorothiazid | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $716.81 · 22 records | AstraZeneca Pharmaceuticals LP | AIRSUPRA, BREZTRI, CAPLYTA, FARXIGA, MOUNJARO, NURTEC ODT, OTEZLA, QULIPTA, REPATHA, REXULTI, TRELEGY ELLIPTA, UBRELVY, VRAYLAR, Veozah, Wegovy, ZAVZPRET, ZEPBOUND | 8 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Farxiga play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with Astellas Pharma US Inc?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error